Antidepressants used for chronic pain on the rise, but are they effective?
New research has found some antidepressants may be effective in treating certain chronic pain conditions, but others lack convincing evidence on their effectiveness. Many people are unaware that some antidepressants (medications used to treat people living with depression) are also being prescribed to treat certain chronic pain conditions. (Source: World Pharma News)
Source: World Pharma News - February 1, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AMJEVITA ™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2) (Source: World Pharma News)
Source: World Pharma News - January 31, 2023 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

CHMP recommends Bayer ’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). (Source: World Pharma News)
Source: World Pharma News - January 30, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
This study, led by researchers at the Johns Hopkins Kimmel Cancer Center, is the latest from an ongoing platform trial formed in 2015 to study immunotherapy treatments before surgery (neoadjuvant) and after surgery (adjuvant) in patients with pancreatic cancer. (Source: World Pharma News)
Source: World Pharma News - January 27, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
13 - 14 March 2023, London, UK. SAE Media Group is proud to present its 4th Annual AI in Drug Discovery Conference, taking place from 13 - 14 March 2023 in London, UK. With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. (Source: World Pharma News)
Source: World Pharma News - January 27, 2023 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chinese researchers. The CEPAMS collaboration used DNA sequencing technology to assemble the genomic sequence of skullcap (Scutellaria barbata) known in China as banzhilian. (Source: World Pharma News)
Source: World Pharma News - January 26, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
The federally funded COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Center in Seattle, was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic. Its vital work to expedite Phase 3 COVID-19 vaccine clinical trials also resulted in a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies. (Source: World Pharma News)
Source: World Pharma News - January 25, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Power of cancer drugs may see boost by targeting newly ID'd pathway
Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome - a cell's complete set of DNA - is most vulnerable while it is being duplicated before a cell divides. Cancer cells constantly are dividing, so their genomes are constantly in jeopardy. Researchers at Washington University School of Medicine in St. Louis have identified a previously unknown signaling pathway cells use to protect their DNA while it is being copied. (Source: World Pharma News)
Source: World Pharma News - January 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study. Consuming soy flour rich in the protein B-conglycinin has the potential to reduce LDL cholesterol levels and lower the risk of metabolic diseases such as atherosclerosis and fatty liver disease, (Source: World Pharma News)
Source: World Pharma News - January 23, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. (Source: World Pharma News)
Source: World Pharma News - January 20, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

500,000 missed out on blood pressure lowering drugs during pandemic
Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK published today in Nature Medicine. The researchers say that thousands of people could suffer an avoidable heart attack or stroke due to delays in starting these vital medications known to stave-off deadly heart and circulatory diseases. (Source: World Pharma News)
Source: World Pharma News - January 19, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries. (Source: World Pharma News)
Source: World Pharma News - January 18, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractical and costly. Investigators at Massachusetts General Hospital (MGH) recently developed an optimized method that improves the accuracy of inserting large DNA segments into a genome. (Source: World Pharma News)
Source: World Pharma News - January 17, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Acquisition of Neogene Therapeutics completed
AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US. (Source: World Pharma News)
Source: World Pharma News - January 16, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

SAE Media Group's 6th annual 3D Cell Culture Conference
8 - 9 February 2023, London, United Kingdom. SAE Media Group's 6th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry. (Source: World Pharma News)
Source: World Pharma News - January 16, 2023 Category: Pharmaceuticals Tags: Featured Events Source Type: news